Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

被引：4

作者：

Eschbach, Ralf S. ^{[1
]}

Hofmann, Markus ^{[1
]}

Spaeth, Lukas ^{[1
]}

Sheikh, Gabriel T. ^{[1
]}

Delker, Astrid ^{[1
]}

Lindner, Simon ^{[1
]}

Jurkschat, Klaus ^{[2
]}

Waengler, Carmen ^{[3
]}

Waengler, Bjoern ^{[4
]}

Schirrmacher, Ralf ^{[5
]}

Tiling, Reinhold ^{[1
]}

Brendel, Matthias ^{[1
]}

Wenter, Vera ^{[1
]}

Dekorsy, Franziska J. ^{[1
]}

Zacherl, Mathias J. ^{[1
]}

Todica, Andrei ^{[1
,6
]}

Ilhan, Harun ^{[1
,6
]}

Grawe, Freba ^{[1
,7
]}

Cyran, Clemens C. ^{[7
]}

Unterrainer, Marcus ^{[7
]}

Ruebenthaler, Johannes ^{[7
]}

Knoesel, Thomas ^{[6
,8
]}

Paul, Tanja ^{[6
,8
]}

Boeck, Stefan ^{[6
,9
]}

Westphalen, Christoph Benedikt ^{[6
,9
]}

Spitzweg, Christine ^{[6
,10
]}

Auernhammer, Christoph J. ^{[6
,10
]}

Bartenstein, Peter ^{[1
,6
]}

Unterrainer, Lena M. ^{[1
]}

Beyer, Leonie ^{[1
,6
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Nucl Med, Munich, Germany

[2] Tech Univ Dortmund, Fak Chem & Chem Biol, Dortmund, Germany

[3] Heidelberg Univ, Med Fac Mannheim, Clin Radiol & Nucl Med, Biomed Chem, Mannheim, Germany

[4] Heidelberg Univ, Med Fac Mannheim, Clin Radiol & Nucl Med, Mol Imaging & Radiochem, Mannheim, Germany

[5] Univ Alberta, Dept Oncol, Div Oncol Imaging, Edmonton, AB, Canada

[6] Univ Hosp Munich, Interdisciplinary Ctr Neuroendocrine Tumours Gast, ENETS Ctr Excellence, Munich, Germany

[7] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany

[8] LMU, Inst Pathol, Munich, Germany

[9] Univ Hosp, Dept Internal Med 3, Munich, Germany

[10] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Internal Med 4, Munich, Germany

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 13卷

关键词：

NET; PET; CT; F-18]SiTATE; somatostatin analogues; somatostatin receptor; molecular imaging; ENETS CONSENSUS GUIDELINES; OCTREOTIDE; INTERNALIZATION; SCINTIGRAPHY; LANREOTIDE; PEPTIDES; PET/CT; SST(2);

D O I：

10.3389/fonc.2023.992316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PurposeSomatostatin analogues (SSA) are frequently used in the treatment of neuroendocrine tumours. Recently, [F-18]SiTATE entered the field of somatostatin receptor (SSR) positron emission tomography (PET)/computed tomography (CT) imaging. The purpose of this study was to compare the SSR-expression of differentiated gastroentero-pancreatic neuroendocrine tumours (GEP-NET) measured by [18F]SiTATE-PET/CT in patients with and without previous treatment with long-acting SSAs to evaluate if SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT. Methods77 patients were examined with standardised [18F]SiTATE-PET/CT within clinical routine: 40 patients with long-acting SSAs up to 28 days prior to PET/CT examination and 37 patients without pre-treatment with SSAs. Maximum and mean standardized uptake values (SUVmax and SUVmean) of tumours and metastases (liver, lymphnode, mesenteric/peritoneal and bones) as well as representative background tissues (liver, spleen, adrenal gland, blood pool, small intestine, lung, bone) were measured, SUV ratios (SUVR) were calculated between tumours/metastases and liver, likewise between tumours/metastases and corresponding specific background, and compared between the two groups. ResultsSUVmean of liver (5.4 +/- 1.5 vs. 6.8 +/- 1.8) and spleen (17.5 +/- 6.8 vs. 36.7 +/- 10.3) were significantly lower (p < 0.001) and SUVmean of blood pool (1.7 +/- 0.6 vs. 1.3 +/- 0.3) was significantly higher (p < 0.001) in patients with SSA pre-treatment compared to patients without. No significant differences between tumour-to-liver and specific tumour-to-background SUVRs were observed between both groups (all p > 0.05). ConclusionIn patients previously treated with SSAs, a significantly lower SSR expression ([18F]SiTATE uptake) in normal liver and spleen tissue was observed, as previously reported for 68Ga-labelled SSAs, without significant reduction of tumour-to-background contrast. Therefore, there is no evidence that SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT.

引用

页数：9

共 50 条

[1] Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
Sheikh, G. T.
Eschbach, R.
Hofmann, M.
Spath, L.
Unterrainer, L. M.
Delker, A.
Lindner, S.
Jurkschat, K.
Wangler, C.
Wangler, B.
Schirrmacher, R.
Tiling, R.
Brendel, M.
Wenter, V.
Dekorsy, F. J.
Zacherl, M. J.
Todica, A.
Ilhan, H.
Grawe, F.
Cyran, C. C.
Unterrainer, M.
Rubenthaler, J.
Knosel, T.
Paul, T.
Boeck, S.
Westphalen, C. Benedikt
Spitzweg, C.
Auernhammer, C. J.
Bartenstein, P.
Beyer, L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S82 - S82
[2] Somatostatin analogue treatment of neuroendocrine tumours
deHerder, WW
vanderLely, AJ
Lamberts, SWJ
POSTGRADUATE MEDICAL JOURNAL, 1996, 72 (849) : 403 - 408
[3] Somatostatin receptor expression in human neuroendocrine tumours.
Nilsson, O
Wigander, A
Lundmark, K
Kolby, L
Billig, H
ForssellAronsson, E
Wangberg, B
Ahlman, H
LABORATORY INVESTIGATION, 1996, 74 (01) : 280 - 280
[4] Head to head comparison of [18F]SiTATE versus [18F]DOPA-PET in patients with neuroendocrine tumors
Roll, W.
Hadjitheodorou, P.
Alevroudis, E.
Kyrou, K.
Adamou, G.
Fesas, A.
Pourkhessalian, M. R.
Kalogirou, C.
Tsechelidis, I.
Schafers, M.
Vrachimis, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S514 - S515
[5] Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours
Beyer, Leonie
Gosewisch, Astrid
Lindner, Simon
Voelter, Friederike
Mittlmeier, Lena M.
Tiling, Reinhold
Brendel, Matthias
Cyran, Clemens C.
Unterrainer, Marcus
Ruebenthaler, Johannes
Auernhammer, Christoph J.
Spitzweg, Christine
Boening, Guido
Gildehaus, F. J.
Jurkschat, Klaus
Wangler, Carmen
Wangler, Bjoern
Schirrmacher, Ralf
Wenter, Vera
Todica, Andrei
Bartenstein, Peter
Ilhan, Harun
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (11) : 3571 - 3581
[6] Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours
Leonie Beyer
Astrid Gosewisch
Simon Lindner
Friederike Völter
Lena M. Mittlmeier
Reinhold Tiling
Matthias Brendel
Clemens C. Cyran
Marcus Unterrainer
Johannes Rübenthaler
Christoph J. Auernhammer
Christine Spitzweg
Guido Böning
F. J. Gildehaus
Klaus Jurkschat
Carmen Wängler
Björn Wängler
Ralf Schirrmacher
Vera Wenter
Andrei Todica
Peter Bartenstein
Harun Ilhan
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 3571 - 3581
[7] Relevance of somatostatin receptor expression in pancreatic neuroendocrine tumors for treatment with somatostatin analogues
Brede, S.
Brabant, G.
Begum, N.
Lehnert, H.
Thorns, C.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (03)
[8] Low-activity [18F]-somatostatin receptor (SSTR) imaging using [18F]SiTATE on a long axial field-of-view PET/CT scanner
Trautwein, Nils F.
Calderon, Eduardo
Linder, Pia M.
Reischl, Gerald
Driessen, Philippe
Lan, Wenhong
Brendlin, Andreas S.
Gross, Thorben
Dittmann, Helmut
Hinterleitner, Martina
la Fougere, Christian
Schmidt, Fabian P.
Kiefer, Lena S.
EJNMMI PHYSICS, 2025, 12 (01):
[9] Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours
Slooter, GD
Mearadji, A
Breeman, WAP
Marquet, RL
de Jong, M
Krenning, EP
van Eijck, CHJ
BRITISH JOURNAL OF SURGERY, 2001, 88 (01) : 31 - 40
[10] Somatostatin Receptor Type 2A and 5 Expression in Pancreatic Neuroendocrine Tumours (PNETs) Patients
Gaoatswe, G.
Woods, C.
McGowan, L.
El Faki, Y.
Tamagno, G.
Sheahan, K.
Swan, N.
O'Shea, D.
IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 : S347 - S347

← 1 2 3 4 5 →